Plain-English translation of NCT04754061 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a naturally occurring substance, to see if it can help people with advanced illness who are experiencing deep emotional and psychological suffering. The study is small (20 people) and is designed to see if this treatment is safe, if people can tolerate it, and whether it might help reduce feelings of hopelessness, anxiety, and depression. People in the trial will take very small daily doses of the medication for up to 4 weeks.
People with advanced illness often experience severe emotional pain—feelings of hopelessness, loss of control, and loss of purpose—that current treatments like antidepressants and therapy don't work well for. These feelings can lead to worse health outcomes and increase thoughts of suicide. This trial exists because there is an urgent need for new, fast-acting treatments that can help people in this situation, and early research suggests this medication might offer hope.
You would take very small capsules containing the medication by mouth once daily from Monday to Friday for up to 4 weeks. The dose starts very low (1 milligram) and can be gradually increased each week based on how you tolerate it. Throughout the study, the research team will check in with you to monitor how you're feeling emotionally and physically, and to watch for any side effects. Your regular palliative care and other medications will continue as usual.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Canada